Kerry Parsons

530 total citations
7 papers, 103 citations indexed

About

Kerry Parsons is a scholar working on Pathology and Forensic Medicine, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kerry Parsons has authored 7 papers receiving a total of 103 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Pathology and Forensic Medicine, 2 papers in Pediatrics, Perinatology and Child Health and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kerry Parsons's work include Cancer Mechanisms and Therapy (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Kerry Parsons is often cited by papers focused on Cancer Mechanisms and Therapy (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Kerry Parsons collaborates with scholars based in United States, France and United Kingdom. Kerry Parsons's co-authors include Raymond G. Watts, M. Brooke Bernhardt, John P. Perentesis, Maureen M. O’Brien, Karen Burns, Jean‐Marie Péron, Shukui Qin, В. В. Бредер, Lünan Yan and Riccardo Lencioni and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Pharmacotherapy and Pediatric Blood & Cancer.

In The Last Decade

Kerry Parsons

7 papers receiving 100 citations

Peers

Kerry Parsons

PPCH

ONCOL

GG

NEURO

EMS

Omar Albanyan United States

Mélanie Dos Santos France

A Castillo Chile

Laura Labonté Canada

Francesco Ghisoni Italy

Mary J. Homer United States

Sheila Rutledge Harding Canada

Jeanette Payne United Kingdom

Taro Koba Japan

Moto Yaga Japan

Omar Albanyan United States

Kerry Parsons

7 ×0.2

PPCH

39 ×1.3

ONCOL

4 ×0.2

GG

2 ×0.1

NEURO

15 ×0.8

EMS

Citations per year, relative to Kerry Parsons Kerry Parsons (= 1×) peers Omar Albanyan

Countries citing papers authored by Kerry Parsons

Since Specialization

Citations

This map shows the geographic impact of Kerry Parsons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry Parsons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry Parsons more than expected).

Fields of papers citing papers by Kerry Parsons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry Parsons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry Parsons. The network helps show where Kerry Parsons may publish in the future.

Co-authorship network of co-authors of Kerry Parsons

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry Parsons. A scholar is included among the top collaborators of Kerry Parsons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry Parsons. Kerry Parsons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Chan, Stephen L., Bruno Sangro, Masatoshi Kudo, et al.. (2024). Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4122–4122. 4 indexed citations

2.

Kudo, Masatoshi, Stephen L. Chan, Bruno Sangro, et al.. (2024). Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 42(23_suppl). 65–65. 1 indexed citations

3.

Burns, Karen, et al.. (2015). Toxicity of Cancer Therapy in Adolescents and Young Adults (AYAs). Seminars in Oncology Nursing. 31(3). 216–226. 37 indexed citations

4.

Watts, Raymond G. & Kerry Parsons. (2013). Chemotherapy medication errors in a pediatric cancer treatment center: Prospective characterization of error types and frequency and development of a quality improvement initiative to lower the error rate. Pediatric Blood & Cancer. 60(8). 1320–1324. 29 indexed citations

5.

Parsons, Kerry, et al.. (2013). Targeted Immunotherapy for High-Risk Neuroblastoma—The Role of Monoclonal Antibodies. Annals of Pharmacotherapy. 47(2). 210–218. 26 indexed citations

6.

Parsons, Kerry, et al.. (2009). Treatment of Osteoporosis/Osteopenia in Pediatric Leukemia and Lymphoma. Annals of Pharmacotherapy. 43(4). 714–720. 5 indexed citations

7.

Parsons, Kerry, et al.. (2006). Rx Mobile: Patient information at the point of care. American Journal of Health-System Pharmacy. 63(5). 456–460. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact